Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | THRB | P10828 | 1/20 | 0.66 |
| ▸ | CNR1 | P21554 | 1/20 | 0.66 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.62 |
| ▸ | HTR2C | P28335 | 1/20 | 0.61 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.58 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.58 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.58 |
| ▸ | PAM | P19021 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | NAAA | Q02083 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL976601 | 1.00 | DGKA (0.77) | DGKAMAPTALDH1A1THRBCNR1 | |
| SCHEMBL19376381 | 1.00 | DGKA (0.77) | DGKAMAPTALDH1A1THRBCNR1 | |
| SCHEMBL19402727 | 1.00 | DGKA (0.77) | DGKAMAPTALDH1A1THRBCNR1 | |
| SCHEMBL10346903 | 1.00 | DGKA (0.77) | DGKAMAPTALDH1A1THRBCNR1 | |
| SCHEMBL973787 | 1.00 | DGKA (0.77) | DGKAMAPTALDH1A1THRBCNR1 | |
| SCHEMBL3338674 | 1.00 | DGKA (0.77) | DGKAMAPTALDH1A1THRBCNR1 | |
| SCHEMBL5933172 | 1.00 | DGKA (0.77) | DGKAMAPTALDH1A1THRBCNR1 | |
| SCHEMBL974095 | 1.00 | DGKA (0.77) | DGKAMAPTALDH1A1THRBCNR1 | |
| SCHEMBL2678233 | 1.00 | DGKA (0.77) | DGKAMAPTALDH1A1THRBCNR1 | |
| SCHEMBL3344674 | 0.98 | DGKA (0.74) | DGKAMAPTALDH1A1THRBCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230172955-A1 | ETHANOLAMINE-BASED LIPID BIOSYNTHETIC COMPOUNDS, METHOD OF MAKING AND USE THEREOF | METANOI THERAPEUTICS INC (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230172955-A1 | ETHANOLAMINE-BASED LIPID BIOSYNTHETIC COMPOUNDS, METHOD OF MAKING AND USE THEREOF | METANOI THERAPEUTICS INC (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230144385-A1 | ETHANOLAMINE FORMULATION FOR TREATING EPITHELIAL OVARIAN CARCINOMA | METANOI THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230144385-A1 | ETHANOLAMINE FORMULATION FOR TREATING EPITHELIAL OVARIAN CARCINOMA | METANOI THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230144385-A1 | ETHANOLAMINE FORMULATION FOR TREATING EPITHELIAL OVARIAN CARCINOMA | METANOI THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20190262366-A1 | ETHANOLAMINE-BASED LIPID BIOSYNTHETIC COMPOUNDS, METHOD OF MAKING AND USE THEREOF | CANTUARIA, GUILHERME H.C. | 2019-08-29 | — | — | US | disclosed |
| US-20170273995-A1 | ETHANOLAMINE-BASED LIPID BIOSYNTHETIC COMPOUNDS, METHOD OF MAKING AND USE THEREOF | CANTUARIA, GUILHERME H.C. | 2017-09-28 | — | — | US | disclosed |
| US-20170273995-A1 | ETHANOLAMINE-BASED LIPID BIOSYNTHETIC COMPOUNDS, METHOD OF MAKING AND USE THEREOF | CANTUARIA, GUILHERME H.C. | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190262366-A1 | ETHANOLAMINE-BASED LIPID BIOSYNTHETIC COMPOUNDS, METHOD OF MAKING AND USE THEREOF | PHOSPHO1, SGMS2, CHKB | DGKA 171/4885MAPT 4121/4885ALDH1A1 657/4885 |
| US-20230144385-A1 | ETHANOLAMINE FORMULATION FOR TREATING EPITHELIAL OVARIAN CARCINOMA | PHOSPHO1, EGLN3, HIF1AN | DGKA 1666/4885MAPT 2393/4885ALDH1A1 1764/4885 |
| US-20170273995-A1 | ETHANOLAMINE-BASED LIPID BIOSYNTHETIC COMPOUNDS, METHOD OF MAKING AND USE THEREOF | PHOSPHO1, SGMS2, CHKB | DGKA 171/4885MAPT 4121/4885ALDH1A1 657/4885 |
| US-20230172955-A1 | ETHANOLAMINE-BASED LIPID BIOSYNTHETIC COMPOUNDS, METHOD OF MAKING AND USE THEREOF | PHOSPHO1, SGMS2, CHKB | DGKA 171/4885MAPT 4121/4885ALDH1A1 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.